The Conversation (0)
Teligent (NASDAQ:TLGT) has announced it has received approval from the FDA for its abbreviated new drug application (ANDA) of desonide ointment, 0.05 percent. As quoted in the press release: is is Teligent’s second approval of 2019, and its thirty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. Based on recent IQVIA data from …
Teligent (NASDAQ:TLGT) has announced it has received approval from the FDA for its abbreviated new drug application (ANDA) of desonide ointment, 0.05 percent.
As quoted in the press release:
is is Teligent’s second approval of 2019, and its thirty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
Based on recent IQVIA data from January 2019, the total addressable market for this product is approximately $12.5 million.
“This first-review-cycle approval again shows the strength of Teligent’s internal R&D capabilities as we continue to build our portfolio and realize the value of our pipeline,’’ commented Jason Grenfell-Gardner, President and CEO of the Company.
Mr. Grenfell-Gardner continued, “We now have thirty-nine topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”
Latest News
Outlook Reports world
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES